World Journal of Surgery

, Volume 33, Issue 7, pp 1542–1543 | Cite as

Laparoscopic D2 Gastrectomy: Time for a Randomized Trial

  • T. Liakakos
  • P. Patapis
  • A. Charalambopoulos
  • A. Macheras


  1. 1.
    Ryu KW, Kim YW, Lee JH et al (2008) Surgical complications and the risk factors of laparoscopy-assisted distal gastrectomy in early gastric cancer. Ann Surg Oncol 15(6):1625–1631PubMedCrossRefGoogle Scholar
  2. 2.
    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555PubMedCrossRefGoogle Scholar
  3. 3.
    Kawamura H, Homma S, Yokota R et al (2008) Inspection of safety and accuracy of D2 lymph node dissection in laparoscopy-assisted distal gastrectomy. World J Surg 32(11):66–70CrossRefGoogle Scholar
  4. 4.
    Liakakos T, Roukos DH (2008) More controversy than ever—challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960PubMedCrossRefGoogle Scholar
  5. 5.
    Kappas AM, Roukos DH (2002) Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol 9(9):828–830PubMedCrossRefGoogle Scholar
  6. 6.
    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695PubMedCrossRefGoogle Scholar
  7. 7.
    Briasoulis E, Liakakos T, Dova L et al (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939PubMedCrossRefGoogle Scholar
  8. 8.
    Fatouros M, Roukos DH, Arampatzis I et al (2005) Factors increasing local recurrence in breast-conserving surgery. Expert Rev Anticancer Ther 5(4):737–745PubMedCrossRefGoogle Scholar
  9. 9.
    Roukos DH (2008) Linking contralateral breast cancer with genetics. Radiother Oncol 86:139–141PubMedCrossRefGoogle Scholar
  10. 10.
    Fatouros M, Baltoyiannis G, Roukos DH (2008) The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations. Ann Surg Oncol 15(1):21–33PubMedCrossRefGoogle Scholar
  11. 11.
    Roukos DH (2008) Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8(1):29–39PubMedCrossRefGoogle Scholar
  12. 12.
    Roukos DH (2008) Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery. Expert Rev Mol Diagn 8(5):587–597PubMedCrossRefGoogle Scholar
  13. 13.
    Roukos DH, Lykoudis E, Liakakos T (2008) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26(26):4360–4361PubMedCrossRefGoogle Scholar
  14. 14.
    Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358:197 (author reply 198)PubMedCrossRefGoogle Scholar
  15. 15.
    Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636 (author reply 1636)PubMedGoogle Scholar
  16. 16.
    Roukos DH (2009) Assessing both genetic variation (SNPs/ CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2009

Authors and Affiliations

  • T. Liakakos
    • 1
  • P. Patapis
    • 1
  • A. Charalambopoulos
    • 1
  • A. Macheras
    • 1
  1. 1.3rd Surgical DepartmentUniversity of AthensAthensGreece

Personalised recommendations